Overview

This trial is active, not recruiting.

Conditions end stage liver disease, rejection, infection, malignancy, toxicity, diabetes
Sponsor UDA Centro Nacional Hepato-Bilio-Pancreático
Collaborator INSERM UMR-S850, Limoges, France
Start date May 2011
End date February 2015
Trial size 141 participants
Trial identifier NCT01760356, 3PIGREF- 2009 -1165

Summary

To search for suitable pharmacodynamic biomarkers, i.e., with high specificity for calcineurin inhibition and most affected by inter-individual variability, our works aimed at exploring the pharmacodynamics of CNI, the strength and variability of signal translation along the calcineurin pathway, as well as the steps where sources of internal (genetic) or external variability are the most influential.

In order to achieve this, we assessed simultaneously NFAT1 translocation into the nucleus of peripheral blood mononuclear cells (PBMC) (NFTA1 being the main NAFT isoform in resting and activated lymphocytes), the intracellular expression of IL-2 in CD3+, CD4+ and CD8+ T cell subsets and the membrane expression of CD25 (IL-2Rα), a surface marker of T cells activation, in T cells at large. A non-interventional clinical trial was set up in healthy volunteers, patients registered on a liver transplantation waiting list (WLP) and liver transplant recipients (LTR). A different question was addressed in each group: The healthy volunteer study (n=35): explored TAC PD along the calcineurin pathway by exposing PBMC ex-vivo; modelled signal translation along this cascade; examined the interindividual variability of TAC PD parameters; and investigated the sources of the variability observed and their contribution at each step of the calcineurin pathway. Furthermore, it allowed us to evaluate the analytical variability of our techniques as well as the intra-individual variability of TAC PD parameters. WLP (n=19) were enrolled to confirm in patients with liver diseases the results obtained in healthy volunteers, as well as to test the potential influence of their initial disease on the ex-vivo pharmacodynamics of TAC. The aims of the transversal study of LTR on CNI (n=80) were to further explore the interindividual variability in the PD of CNI in realistic clinical conditions, i.e. in situations of residual PD activities under tacrolimus or cyclosporine exposure, and the potential pharmacogenetic (PG) sources of such variability. The (still small) group of liver transplant patients (n=9) enrolled immediately before transplantation and followed-up with serial monitoring along the first year post-transplantation was intended to explore the relationships between CNI PD and clinical responses.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients. The number proposed is 50.
To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions. The number proposed is 12.
To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients. The number proposed is 10.
Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses. The number proposed is 20.

Primary Outcomes

Measure
Change in Percentage of expression of CD25High in CD3, CD4 and CD8 T Lymphocytes.
time frame: All subjects at the inclusion. Patients from the longitudinal cohort: at 0, 30, 90, 180 and 360 days post transplantation.
Pharmacogenetic investigations
time frame: At the moment of the inclusion for all cohorts.
Anticalcineurin drug concentration through levels
time frame: At the moment of the inclusion and at each regular office visit during check up.
Change in Mean Fluorescence Intensity of NFAT1 Nuclear Translocation Inhibition in PMBC nuclei.
time frame: All subjects at the inclusion. Patients from the longitudinal cohort: at 0, 30, 90, 180 and 360 days post transplantation.
Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.
time frame: All subjects at the inclusion. Patients from the longitudinal cohort: at 0, 30, 90, 180 and 360 days post transplantation.

Secondary Outcomes

Measure
Acute Cellular Rejection Mild, Moderate and Severe
time frame: Within the year of follow up.
Infection Episodes which requiere anmicrobials treament
time frame: Within the year of follow up
Neurotoxicity to CNIs
time frame: Within the year of follow up
Nephrotoxicity to CNIs
time frame: Within the year of follow up
Malignancies
time frame: Within the year of follow up
Post transplant Diabetes
time frame: Within the year of follow up
Cardiovascular disease, post transplant blood pressure augmentation
time frame: Within the year of follow up
Death
time frame: Within the year of follow up
Post transplant surgical complications
time frame: Within the year of follow up

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: Healthy volunteers: - Age: 18 to 70 years. - Ethnicity: Hispanic, African American. - Gender: male and female. - Condition: healthy. - Informed consent: granted and signed informed consent at the time of inclusion and agreement to comply with all the procedures included in the protocol. Waiting List Patients: - Age: 18 to 70 years. - Ethnicity: Hispanic, African American. - Gender: male and female. - Being active on the waiting list for liver transplantation - Informed consent: granted and signed at the time of inclusion and agreement to comply with all the procedures included in the protocol. Transplant Patients: - Age: 18 to 70 years. - Ethnicity: Hispanic, African American. - Gender: male and female. - Drug therapy: cyclosporine or tacrolimus, with or without mycophenolic acid derivatives and/or corticosteroids. - Informed consent: granted and signed at the time of inclusion and agreement to comply with all the procedures included in the protocol. Exclusion Criteria: Healthy volunteers: - pregnancy - breastfeeding - chronic drug treatment - non healthy Waiting List Patients: - Patients with previous transplant. - Patients with more of one transplanted organ. - Patients on anticalcineurin drugs. - Patients with impaired renal function - creatinine clearance ≤ 20 ml/min. Transplant Patients: - Pregnant or breastfeeding. - Patients with prior retransplantation. - Patients with more of one transplanted organ. - Patients with impaired renal function - creatinine clearance ≤ 20 ml/min. - Everolimus indication at any time during treatment.

Additional Information

Official title Study of Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Relationships of Anticalcineurin Drugs: Tacrolimus and Cyclosporin in Liver Transplant Recipients.
Principal investigator Ofelia M Noceti, PhD, PharmD
Description The research will be conducted under the rules of Good Clinical Practice, Good Laboratory Practice of the International Conference on Harmonisation (ICH)and the Principles of Declaration of Helsinki. Groups of study are included once inclusion/exclusion criteria were verified and after written informed consent was given: healthy volunteers, patients of the waiting list for liver transplantation, liver transplant recipients on tacrolimus and cyclosporine and a longitudinal cohort of patients enrolled since the waiting list for transplantation. From this instance proceed the sampling plan. Considering potential dropouts or withdrawals during the study, the intention is to recruit an additional 10% to compensate for the cohorts, as they allow. The study design does not suppose applying masking methods, since it is an open study. All data required in the registration forms will be recorded, however in case of persistent failure, will be properly documented the reasons for the absence. Each instance will merit a particular analysis, dated and signed. Models could be used to estimate the impact of bias due to potential missing data, and if applicable will be complemented with a sensibility analysis. Loading data will be conducted electronically. Data will be validated according to the data management plan, jointly defined by the principal investigator and the biostatistician, including freezing and thawing processes. Pharmacokinetic, pharmacogenetic and pharmacodynamic modeling will be done using R software. Data back ups will be run everyday, and will be archived on tape and a USB storage drive. Besides self monitoring procedures, the study may be audited by the health authority (during the course of the study or even when it is completed), to assess compliance with the standards of Good Clinical Practice. Atypical results if any, will be handled according to the criteria of results outside of specification. If re-analysis of samples will occur, they will be properly documented. Sample size calculation includes the percentage of occurrence of acute cellular rejection and adverse events, as reported by the National Liver Transplant Program and the possible rates of abandonment or premature retirement of the in study subjects. Under national rates, will be studied at least 30 healthy volunteers, 50 patients and 12 patients with end stage liver disease enlisted for liver transplantation, with serial follow-up during the first year. Statistical analysis will be performed according to the principle of "intention to treat", and will be the responsible for at least one specialist in biostatistics. It will be developed a descriptive analysis of all variables collected. Categorical variables will be expressed in percentages and number of observations. Continuous variables will be expressed as mean and coefficient of variation or median and 25th and 75th percentiles, minimum and maximum. Lof transformations will be held whenever needed. The variables will be compared between groups according to the patient's original listing (intention to treat). They will be calculated and presented the estimated relative risks and their effect with 95% confidence intervals. For comparison of categorical variables, it will be used the Chi-square test or Fisher's exact test as appropriate. For comparison of continuous variables, it will be used the test "t" of Student. For variables that develop with time, they will be represented by Kaplan-Meier curves and compared using the "log-rank" test. Their relative risk with 95% confidence interval will be calculated. To identify variables associated with different responses multivariate linear analysis, logistic or Cox proportional will be used. All analyzes will be performed with hypothesis testing and a 2-tailed significance level of 5%. The program used will be R. Multivariate analysis will be held corrected according Bonferroni's criteria. We have established standard operating procedures to describe blood collection instances, biological fluids sampling circuit, evaluation of the candidates to include in the study, verification of the inclusion criteria, monitoring of patients during the study, record of undesirable events and report of adverse drug reactions, terminating tracking.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by UDA Centro Nacional Hepato-Bilio-Pancreático.